Global Narcolepsy Treatment market to Grow at 5.1% CAGR ... Usage: Approved for improving wakefulness in adults with EDS due to narcolepsy or obstructive sleep apnea. Market Position: Expected ...

The FDA has expanded the approval of Lumryz (sodium oxybate) extended-release oral suspension to include treatment of pediatric narcolepsy.

Many people require a combination of treatments. Provigil (modafinil) is a wakefulness-promoting agent. The U.S. Food and Drug Administration (FDA) has approved it to improve wakefulness in adults ...

Neuraxpharm Group (Neuraxpharm), a leading European specialty pharmaceutical company focused on the treatment of central nervous system (CNS) disorders, announces today that it has acquired at the end ...

Neuraxpharm Group (Neuraxpharm), a leading European specialty pharmaceutical company focused on the treatment of central nervous system (CNS) disorders, announces today that it has acquired at the end ...

Many people require a combination of treatments ... has approved it to improve wakefulness in adults with EDS associated with ...

The narcolepsy treatment market is set for substantial growth, with projections indicating an increase from USD 5,301.6 million in 2024 to USD 8,718.3 million by 2034, reflecting a compound annual ...